Pulse Biosciences (NASDAQ:PLSE) Insider Kevin Patrick Danahy Sells 20,000 Shares

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00. Following the completion of the transaction, the insider owned 43,298 shares of the company’s stock, valued at $1,018,801.94. This trade represents a 31.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kevin Patrick Danahy also recently made the following trade(s):

• On Tuesday, February 17th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $23.63, for a total transaction of $472,600.00.
• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $21.45, for a total value of $429,000.00.
• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $25.20, for a total transaction of $504,000.00.

Pulse Biosciences Stock Performance

PLSE opened at $23.67 on Wednesday. Pulse Biosciences, Inc has a twelve month low of $12.56 and a twelve month high of $26.30. The firm has a market cap of $1.60 billion, a PE ratio of -20.95 and a beta of 1.77. The firm’s fifty day moving average is $15.75 and its two-hundred day moving average is $15.90.

Wall Street Analysts Forecast Growth

PLSE has been the topic of a number of recent analyst reports. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pulse Biosciences currently has an average rating of “Hold” and an average target price of $26.00.

Institutional Trading of Pulse Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AlphaQuest LLC lifted its stake in shares of Pulse Biosciences by 184.5% in the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after buying an additional 5,748 shares in the last quarter. Westside Investment Management Inc. raised its holdings in shares of Pulse Biosciences by 10.5% in the 2nd quarter. Westside Investment Management Inc. now owns 64,290 shares of the company’s stock worth $970,000 after acquiring an additional 6,135 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Pulse Biosciences by 44.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after acquiring an additional 1,372 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after purchasing an additional 680 shares in the last quarter. 76.95% of the stock is owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.